DMD and Duchenne muscular dystrophy: ,2 In Duchenne muscular dystrophy (DMD), approved ASO therapies utilize a stabilized oligonucleotide chemistry known as phosphorodiamidate morpholino oligomers (PMOs) to enable frameshift correction by exon skipping, ultimately resulting in production of a truncated but functional dystrophin protein.3